Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 3, 2025

Earnings live: Berkshire Hathaway profits rise, Beyond Meat postpones earnings, with Palantir results on deck

View original at finance.yahoo.com
Earnings live: Berkshire Hathaway profits rise, Beyond Meat postpones earnings, with Palantir results on deck The third quarter earnings season is in full swing, with several AI players reporting results this week, including Palantir (PLTR), AMD (AMD), and Supermicro (SMCI)…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • As of Oct. 31, 64% of S&P 500 companies have reported results, and analysts are expecting a 10.7% jump in earnings per share during the third quarter

    80% confidence
  • We're seeing continued signs of stabilization across our core markets, as well as positive growth in AI

    80% confidence
  • The cooling in the labor market has been gradual

    80% confidence
  • The announcement we made a few days ago was not really financially driven, and it's not even really AI driven — not right now, at least. It's culture

    80% confidence
  • We are committed to operating like the world's largest startup, and that means removing layers

    80% confidence
  • AWS is growing at a pace we haven't seen since 2022, re-accelerating to 20.2% YoY

    80% confidence
  • Analysts expected S&P 500 companies to report a 7.9% jump in earnings per share during the third quarter coming into the quarter

    80% confidence
  • We are incredibly excited about the strength we're seeing across our products and services, and we expect the December quarter's revenue to be the best ever for the company and the best ever for iPhone

    80% confidence
  • Our third quarter results exceeded expectations, underscoring the strength of our strategy and the resilience of our business model

    80% confidence
  • As a result of these factors, we expect margin pressure within our Pharmacy Benefit Services segment over the next two years

    80% confidence
  • Partners operating in government programs like Medicaid and Medicare are facing significant financial and affordability pressures

    80% confidence
  • We continue to see strong momentum and growth across Amazon as AI drives meaningful improvements in every corner of our business

    80% confidence
  • AI-related revenue approximately doubled year over year in Q3

    80% confidence
  • You're going to see us continue to be very aggressive in investing in capacity because we see the demand

    80% confidence
  • If 10.7% EPS growth holds, it would mark the fourth straight quarter of double-digit earnings growth but a deceleration from the 12% earnings growth reported in Q2 of this year

    80% confidence
  • The iPhone 17 is facing supply constraints due to high demand

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com